A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
A phase 2 trial of TAS6417 in non-small-cell lung cancer, run by Taiho Oncology, Inc., now recruiting.
Overview
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. is a phase 2 interventional study registered as NCT05967689 by Taiho Oncology, Inc., with 220 participants planned, started 2023-07-31 and due to reach its primary completion in 2028-08-31. Interventions recorded: TAS6417, CYP Cocktail and Transporter Cocktail.
Similar pages
not linked directly; found by shared links- TrialStudy of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Shares Araris Biotech (Taiho), Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Shares Araris Biotech (Taiho) and the tag pipeline.
- TrialPhase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Shares Araris Biotech (Taiho) and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Shares Non-small-cell lung cancer and the tag pipeline.